ImClone starts Ph II IMC-A12 enrollment

ImClone Systems, a US leader in the development and commercialization of novel antibodies to treat cancer, says that a Phase II clinical trial of IMC-A12, its fully-human, IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody, in adolescents and adult patients with several types of soft-tissue sarcoma has opened for patient enrollment.

"This Phase II study of IMC-A12 builds on a biological rationale that suggests that the insulin-like growth factor receptor may confer a treatment advantage to these unique cancers versus conventional chemotherapy agents which often induce less than optimal results," said Eric Rowinsky, chief medical officer of ImClone.

This multinational study will evaluate the efficacy of IMC-A12 in adult and adolescent (aged